Working… Menu

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02405221
Recruitment Status : Recruiting
First Posted : April 1, 2015
Last Update Posted : May 8, 2019
National Cancer Institute (NCI)
PapiVax Biotech, Inc.
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2022